Trastuzumab deruxtecan induces durable responses in HER2-expressing advanced solid tumors
Click Here to Manage Email Alerts
A phase 2 trial of trastuzumab deruxtecan met a prespecified target for objective response rate and showed clinically meaningful, durable responses across multiple HER2-expressing advanced solid tumors, according to a company press release.
Trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo), an HER2-directed antibody-drug conjugate approved for certain patients with breast, lung and gastric cancer, also exhibited a safety profile consistent with that observed in other trials.
The open-label, phase 2 DESTINY-PanTumor02 trial is evaluating the efficacy and safety of trastuzumab deruxtecan, dosed at 5.4 mg/kg, in patients with locally advanced, unresectable or metastatic previously treated, HER2-expressing solid tumors not eligible for curative therapy. The trial has enrolled 268 patients with biliary tract, bladder, cervical, endometrial, ovarian, pancreatic and rare forms of cancer at sites across Asia, Europe and North America.
Investigator-assessed objective response rate serves as the primary endpoint, with investigator-assessed duration of response as a key secondary endpoint.
“Enhertu has already demonstrated its potential to improve outcomes for patients with HER2-targetable breast, gastric and lung cancers, and these positive initial results in other tumor settings with significant unmet need are very encouraging,” Cristian MassacesiMD, chief medical officer and oncology chief development officer for AstraZeneca, said in a press release. “The DESTINY-PanTumor02 results mark an important step forward in our understanding of the potential role of Enhertu across multiple HER2-expressing tumor types.”
Data will be presented at a future medical meeting.
Collapse
Press Release
Read more about
Click Here to Manage Email Alerts